“During the session, Dr Castro and I were gratified to note that in response to a question from the moderator, virtually every cessation expert in the room confirmed that increased cough and phlegm are identified as a barrier to quitting by patients.
“We believe these results continue to not only support the implementation of phase 3 programs for the oral compounds, but also confirm inhaled INV102 (nadolol) as a target for chronic airway diseases including asthma, COPD and cystic fibrosis.” Invion is actively pursuing license and co-development partners for the INV102 franchise.
Got be not to far away for some license deal.
Ann: Phase 2 data presented to American Thoracic Society-IVX.AX, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.59M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.5¢ | 12.5¢ | $14.25K | 106.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 142640 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 25865 | 2 |
View Market Depth
| Last trade - 10.21am 23/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |